JP2019502755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502755A5 JP2019502755A5 JP2018553846A JP2018553846A JP2019502755A5 JP 2019502755 A5 JP2019502755 A5 JP 2019502755A5 JP 2018553846 A JP2018553846 A JP 2018553846A JP 2018553846 A JP2018553846 A JP 2018553846A JP 2019502755 A5 JP2019502755 A5 JP 2019502755A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- pyridin
- difluoro
- tetrazol
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 69
- -1 NH 2 Chemical group 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 42
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 42
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 35
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 31
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 125000001153 fluoro group Chemical group F* 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 claims 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 241000222122 Candida albicans Species 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- DIHPVRJYXAIEQR-ZSXSBBPPSA-N FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C=1C=NC(=CC=1)C(C(F)(F)F)O)(F)F)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C=1C=NC(=CC=1)C(C(F)(F)F)O)(F)F)(CN1N=NN=C1)O DIHPVRJYXAIEQR-ZSXSBBPPSA-N 0.000 claims 3
- 208000031888 Mycoses Diseases 0.000 claims 3
- 241000223230 Trichosporon Species 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- QPRQEDXDYOZYLA-UHFFFAOYSA-N 2-methyl-1-butanol Substances CCC(C)CO QPRQEDXDYOZYLA-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 201000007336 Cryptococcosis Diseases 0.000 claims 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims 2
- CHCBEOJABAZIOY-ZSXSBBPPSA-N FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC(=NC=C1)C(C(F)(F)F)O)(F)F)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC(=NC=C1)C(C(F)(F)F)O)(F)F)(CN1N=NN=C1)O CHCBEOJABAZIOY-ZSXSBBPPSA-N 0.000 claims 2
- VKOOJCSMWOOQHZ-HKBQPEDESA-N FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC2=C(NC(=N2)C(F)(F)F)C=C1)(F)F)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC2=C(NC(=N2)C(F)(F)F)C=C1)(F)F)(CN1N=NN=C1)O VKOOJCSMWOOQHZ-HKBQPEDESA-N 0.000 claims 2
- HAWNZENDCHYEQZ-JYUUXGOASA-N FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)C(C(F)(F)F)O)(F)F)(CN1C=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)C(C(F)(F)F)O)(F)F)(CN1C=NN=C1)O HAWNZENDCHYEQZ-JYUUXGOASA-N 0.000 claims 2
- CHPQEFIJCCDEFH-FLDQDSGZSA-N FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)C(C(F)(F)F)O)(F)F)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)C(C(F)(F)F)O)(F)F)(CN1N=NN=C1)O CHPQEFIJCCDEFH-FLDQDSGZSA-N 0.000 claims 2
- BIFXOHAXTPHDQX-XIFFEERXSA-N FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)C(C)(C)O)(F)F)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)C(C)(C)O)(F)F)(CN1N=NN=C1)O BIFXOHAXTPHDQX-XIFFEERXSA-N 0.000 claims 2
- NIGBDUZMVMRPER-PMERELPUSA-N FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)F)(F)F)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)F)(F)F)(CN1N=NN=C1)O NIGBDUZMVMRPER-PMERELPUSA-N 0.000 claims 2
- IACOWBALBATJAE-YTTGMZPUSA-N FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCC(CC1)C1=CC=C(C#N)C=C1)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCC(CC1)C1=CC=C(C#N)C=C1)(CN1N=NN=C1)O IACOWBALBATJAE-YTTGMZPUSA-N 0.000 claims 2
- YTAFWBOGMBEQFX-HKBQPEDESA-N FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC(=C(C#N)C=C1)F)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC(=C(C#N)C=C1)F)(CN1N=NN=C1)O YTAFWBOGMBEQFX-HKBQPEDESA-N 0.000 claims 2
- QKWUMLTVHKNXNQ-HKBQPEDESA-N FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C#N)C=C1)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C#N)C=C1)(CN1N=NN=C1)O QKWUMLTVHKNXNQ-HKBQPEDESA-N 0.000 claims 2
- PWJHESUJMQFMLX-PMERELPUSA-N FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C1=NC=C(C#N)C=C1)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C1=NC=C(C#N)C=C1)(CN1N=NN=C1)O PWJHESUJMQFMLX-PMERELPUSA-N 0.000 claims 2
- MOTYPNJIEOKQIP-PMERELPUSA-N FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C=1C=CC(=NC=1)C#N)(CN1N=NN=C1)O Chemical compound FC1=C(C=CC(=C1)F)[C@](C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C=1C=CC(=NC=1)C#N)(CN1N=NN=C1)O MOTYPNJIEOKQIP-PMERELPUSA-N 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- 241000228143 Penicillium Species 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 208000002474 Tinea Diseases 0.000 claims 2
- 241000223104 Trypanosoma Species 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000000855 fungicidal effect Effects 0.000 claims 2
- 239000000417 fungicide Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Substances CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims 1
- ZMYFCFLJBGAQRS-IRXDYDNUSA-N (2R,3S)-epoxiconazole Chemical compound C1=CC(F)=CC=C1[C@@]1(CN2N=CN=C2)[C@H](C=2C(=CC=CC=2)Cl)O1 ZMYFCFLJBGAQRS-IRXDYDNUSA-N 0.000 claims 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims 1
- PXMNMQRDXWABCY-UHFFFAOYSA-N 1-(4-chlorophenyl)-4,4-dimethyl-3-(1H-1,2,4-triazol-1-ylmethyl)pentan-3-ol Chemical compound C1=NC=NN1CC(O)(C(C)(C)C)CCC1=CC=C(Cl)C=C1 PXMNMQRDXWABCY-UHFFFAOYSA-N 0.000 claims 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims 1
- UFNOUKDBUJZYDE-UHFFFAOYSA-N 2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol Chemical compound C1=NC=NN1CC(O)(C=1C=CC(Cl)=CC=1)C(C)C1CC1 UFNOUKDBUJZYDE-UHFFFAOYSA-N 0.000 claims 1
- MNHVNIJQQRJYDH-UHFFFAOYSA-N 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound N1=CNC(=S)N1CC(C1(Cl)CC1)(O)CC1=CC=CC=C1Cl MNHVNIJQQRJYDH-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims 1
- 241000235389 Absidia Species 0.000 claims 1
- 208000000230 African Trypanosomiasis Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 241000893451 Arthroderma Species 0.000 claims 1
- 201000002909 Aspergillosis Diseases 0.000 claims 1
- 241000228212 Aspergillus Species 0.000 claims 1
- 241000228197 Aspergillus flavus Species 0.000 claims 1
- 241001225321 Aspergillus fumigatus Species 0.000 claims 1
- 208000036641 Aspergillus infections Diseases 0.000 claims 1
- 241000228245 Aspergillus niger Species 0.000 claims 1
- 239000005730 Azoxystrobin Substances 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 102000003846 Carbonic anhydrases Human genes 0.000 claims 1
- 108090000209 Carbonic anhydrases Proteins 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 241000223203 Coccidioides Species 0.000 claims 1
- 241000223205 Coccidioides immitis Species 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 239000005757 Cyproconazole Substances 0.000 claims 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 1
- 206010012504 Dermatophytosis Diseases 0.000 claims 1
- 241001480035 Epidermophyton Species 0.000 claims 1
- 239000005767 Epoxiconazole Substances 0.000 claims 1
- URNJLBHXKCXXHW-UHFFFAOYSA-N FC1=C(C=C(C=C1)F)C(C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)C(C(F)(F)F)O)(F)F)(CN1N=NN=C1)O Chemical compound FC1=C(C=C(C=C1)F)C(C(C1=NC=C(C=C1)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(C=C1)C(C(F)(F)F)O)(F)F)(CN1N=NN=C1)O URNJLBHXKCXXHW-UHFFFAOYSA-N 0.000 claims 1
- KRYWZZQSXIHLIW-UHFFFAOYSA-N FC1=C(C=CC(=C1)F)C(C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C=1C=CC(=NC=1)C(CC(F)(F)F)O)(CN1N=CN=C1)O Chemical compound FC1=C(C=CC(=C1)F)C(C(F)(F)C1=CC=C(C=N1)C1=CC=C(C=C1)N1CCN(CC1)C=1C=CC(=NC=1)C(CC(F)(F)F)O)(CN1N=CN=C1)O KRYWZZQSXIHLIW-UHFFFAOYSA-N 0.000 claims 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical class [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 claims 1
- 239000005784 Fluoxastrobin Substances 0.000 claims 1
- 239000005785 Fluquinconazole Substances 0.000 claims 1
- 241000427940 Fusarium solani Species 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims 1
- 235000014683 Hansenula anomala Nutrition 0.000 claims 1
- 244000286779 Hansenula anomala Species 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 241000228404 Histoplasma capsulatum Species 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 1
- 241000308509 Hortaea Species 0.000 claims 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims 1
- 102100021695 Lanosterol 14-alpha demethylase Human genes 0.000 claims 1
- 101710146773 Lanosterol 14-alpha demethylase Proteins 0.000 claims 1
- 241000222722 Leishmania <genus> Species 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 239000005868 Metconazole Substances 0.000 claims 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 1
- 241001480037 Microsporum Species 0.000 claims 1
- 241000893980 Microsporum canis Species 0.000 claims 1
- 241001460074 Microsporum distortum Species 0.000 claims 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 1
- 241000235395 Mucor Species 0.000 claims 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 1
- 208000010195 Onychomycosis Diseases 0.000 claims 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 claims 1
- 206010033767 Paracoccidioides infections Diseases 0.000 claims 1
- 201000000301 Paracoccidioidomycosis Diseases 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- 241000235648 Pichia Species 0.000 claims 1
- 241000224016 Plasmodium Species 0.000 claims 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims 1
- 241000233872 Pneumocystis carinii Species 0.000 claims 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims 1
- 239000005822 Propiconazole Substances 0.000 claims 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 1
- 239000005825 Prothioconazole Substances 0.000 claims 1
- 239000005869 Pyraclostrobin Substances 0.000 claims 1
- 241000293825 Rhinosporidium Species 0.000 claims 1
- 240000005384 Rhizopus oryzae Species 0.000 claims 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 claims 1
- 229930182692 Strobilurin Natural products 0.000 claims 1
- 239000005839 Tebuconazole Substances 0.000 claims 1
- 201000010618 Tinea cruris Diseases 0.000 claims 1
- 206010056131 Tinea versicolour Diseases 0.000 claims 1
- 241000223238 Trichophyton Species 0.000 claims 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 claims 1
- 241000223229 Trichophyton rubrum Species 0.000 claims 1
- 241000893966 Trichophyton verrucosum Species 0.000 claims 1
- 241001480050 Trichophyton violaceum Species 0.000 claims 1
- 241001634961 Trichosporon asahii Species 0.000 claims 1
- 239000005857 Trifloxystrobin Substances 0.000 claims 1
- 241000223105 Trypanosoma brucei Species 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 206010061418 Zygomycosis Diseases 0.000 claims 1
- 241000222126 [Candida] glabrata Species 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- WFDXOXNFNRHQEC-GHRIWEEISA-N azoxystrobin Chemical compound CO\C=C(\C(=O)OC)C1=CC=CC=C1OC1=CC(OC=2C(=CC=CC=2)C#N)=NC=N1 WFDXOXNFNRHQEC-GHRIWEEISA-N 0.000 claims 1
- 229940095731 candida albicans Drugs 0.000 claims 1
- 208000032343 candida glabrata infection Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 201000003486 coccidioidomycosis Diseases 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims 1
- 238000002845 discoloration Methods 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- UFEODZBUAFNAEU-NLRVBDNBSA-N fluoxastrobin Chemical compound C=1C=CC=C(OC=2C(=C(OC=3C(=CC=CC=3)Cl)N=CN=2)F)C=1C(=N/OC)\C1=NOCCO1 UFEODZBUAFNAEU-NLRVBDNBSA-N 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000024386 fungal infectious disease Diseases 0.000 claims 1
- 244000053095 fungal pathogen Species 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 150000003278 haem Chemical class 0.000 claims 1
- 208000029080 human African trypanosomiasis Diseases 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical group C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims 1
- 229940058690 lanosterol Drugs 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- XWPZUHJBOLQNMN-UHFFFAOYSA-N metconazole Chemical compound C1=NC=NN1CC1(O)C(C)(C)CCC1CC1=CC=C(Cl)C=C1 XWPZUHJBOLQNMN-UHFFFAOYSA-N 0.000 claims 1
- 229910052750 molybdenum Inorganic materials 0.000 claims 1
- 239000011733 molybdenum Substances 0.000 claims 1
- 201000007524 mucormycosis Diseases 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 201000000317 pneumocystosis Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 claims 1
- HZRSNVGNWUDEFX-UHFFFAOYSA-N pyraclostrobin Chemical compound COC(=O)N(OC)C1=CC=CC=C1COC1=NN(C=2C=CC(Cl)=CC=2)C=C1 HZRSNVGNWUDEFX-UHFFFAOYSA-N 0.000 claims 1
- 201000002612 sleeping sickness Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000005882 tinea unguium Diseases 0.000 claims 1
- ONCZDRURRATYFI-TVJDWZFNSA-N trifloxystrobin Chemical compound CO\N=C(\C(=O)OC)C1=CC=CC=C1CO\N=C(/C)C1=CC=CC(C(F)(F)F)=C1 ONCZDRURRATYFI-TVJDWZFNSA-N 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273167P | 2015-12-30 | 2015-12-30 | |
| US62/273,167 | 2015-12-30 | ||
| PCT/US2016/069217 WO2017117393A1 (en) | 2015-12-30 | 2016-12-29 | Metalloenzyme inhibitor compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502755A JP2019502755A (ja) | 2019-01-31 |
| JP2019502755A5 true JP2019502755A5 (enExample) | 2019-08-15 |
| JP6803923B2 JP6803923B2 (ja) | 2020-12-23 |
Family
ID=59225927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553846A Expired - Fee Related JP6803923B2 (ja) | 2015-12-30 | 2016-12-29 | 金属酵素阻害化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10464922B2 (enExample) |
| EP (1) | EP3397629B1 (enExample) |
| JP (1) | JP6803923B2 (enExample) |
| KR (1) | KR102240920B1 (enExample) |
| CN (1) | CN108779094B (enExample) |
| AU (1) | AU2016380349B2 (enExample) |
| BR (1) | BR112018013522A2 (enExample) |
| CA (1) | CA3006469C (enExample) |
| EA (1) | EA038421B1 (enExample) |
| MX (1) | MX376201B (enExample) |
| TW (1) | TWI623528B (enExample) |
| WO (1) | WO2017117393A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX382905B (es) | 2014-03-19 | 2025-03-13 | Viamet Pharmaceuticals Nc Inc | 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)-3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion. |
| JP2017514790A (ja) | 2014-03-19 | 2017-06-08 | ヴィアメット ファーマスーティカルズ，インコーポレイテッド | 抗真菌化合物の調製方法 |
| JP6606508B2 (ja) | 2014-03-19 | 2019-11-13 | マイコヴィア ファーマシューティカルズ，インコーポレイテッド | 抗真菌化合物の調製方法 |
| MX371291B (es) | 2014-03-19 | 2020-01-24 | Viamet Pharmaceuticals Nc Inc | 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procedimientos para su preparacion. |
| AU2015231220B2 (en) | 2014-03-19 | 2019-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antifungal compound process |
| JP6572234B2 (ja) | 2014-03-19 | 2019-09-04 | ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド | 抗真菌化合物の調製方法 |
| AU2015231234B2 (en) | 2014-03-19 | 2019-04-04 | Mycovia Pharmaceuticals, Inc. | Antifungal compound process |
| EA037587B1 (ru) | 2014-03-19 | 2021-04-19 | Майковиа Фармасьютикалс, Инк. | Способ получения противогрибковых соединений |
| JP6518683B2 (ja) | 2014-03-19 | 2019-05-22 | ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド | 抗真菌化合物の調製方法 |
| MX391538B (es) | 2015-09-18 | 2025-03-21 | Mycovia Pharmaceuticals Inc | Proceso de compuesto antifungico. |
| WO2019182743A1 (en) * | 2018-03-20 | 2019-09-26 | Innocrin Pharmaceuticals, Inc. | Compositions for the treatment of brain tumors |
| US12357615B2 (en) | 2018-10-11 | 2025-07-15 | Kembi Therapeutics Pty Ltd | Compositions for the treatment of brain tumors |
| WO2022216680A1 (en) | 2021-04-05 | 2022-10-13 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| CN113444131B (zh) * | 2021-06-24 | 2022-10-21 | 鲁东大学 | N-乙酰氨基葡萄糖类化合物及其制备方法和应用 |
| WO2023069613A1 (en) * | 2021-10-20 | 2023-04-27 | Ohio State Innovation Foundation | Arylimidamides for use in treatment of cancers |
| CN115466227B (zh) * | 2022-06-30 | 2024-07-19 | 杭州国瑞生物科技有限公司 | 一种3-(氯甲基)-1-甲基-1h-1,2,4-三唑盐酸盐的制备方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| ATE107176T1 (de) | 1989-12-04 | 1994-07-15 | Searle & Co | System zur transdermalen albuterol applikation. |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| ATE360617T1 (de) * | 1994-06-15 | 2007-05-15 | Otsuka Pharma Co Ltd | Benzoheterocyclische verbindungen verwendbar als vasopressin- oder oxytocin-modulatoren |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| AUPP999799A0 (en) * | 1999-04-27 | 1999-05-20 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| EP2090165A3 (en) * | 2001-04-03 | 2012-03-28 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| JP5266430B2 (ja) * | 2010-04-24 | 2013-08-21 | ヴィアメット ファーマスーティカルズ，インコーポレイテッド | 金属酵素阻害化合物 |
| US9029389B2 (en) * | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
| EA201491386A1 (ru) * | 2012-01-20 | 2014-11-28 | Вайамет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
| AU2013209516A1 (en) * | 2012-01-20 | 2014-08-28 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
| EA201690007A1 (ru) * | 2013-06-12 | 2016-04-29 | Ваймет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
| AU2015231270B2 (en) * | 2014-03-19 | 2019-03-07 | Viamet Pharmaceuticals (NC), Inc. | Antifungal compound process |
-
2016
- 2016-12-29 WO PCT/US2016/069217 patent/WO2017117393A1/en not_active Ceased
- 2016-12-29 JP JP2018553846A patent/JP6803923B2/ja not_active Expired - Fee Related
- 2016-12-29 KR KR1020187022077A patent/KR102240920B1/ko not_active Expired - Fee Related
- 2016-12-29 AU AU2016380349A patent/AU2016380349B2/en not_active Ceased
- 2016-12-29 US US16/066,763 patent/US10464922B2/en not_active Expired - Fee Related
- 2016-12-29 BR BR112018013522A patent/BR112018013522A2/pt not_active Application Discontinuation
- 2016-12-29 CN CN201680076973.0A patent/CN108779094B/zh not_active Expired - Fee Related
- 2016-12-29 MX MX2018008105A patent/MX376201B/es active IP Right Grant
- 2016-12-29 EP EP16882663.4A patent/EP3397629B1/en active Active
- 2016-12-29 EA EA201891539A patent/EA038421B1/ru unknown
- 2016-12-29 CA CA3006469A patent/CA3006469C/en active Active
- 2016-12-30 TW TW105144241A patent/TWI623528B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502755A5 (enExample) | ||
| JP2015504095A5 (enExample) | ||
| JP2016526535A5 (enExample) | ||
| JP2015505841A5 (enExample) | ||
| Wang et al. | Tetrazole hybrids and their antifungal activities | |
| CN108779094B (zh) | 金属酶抑制剂化合物 | |
| AU2021288898A1 (en) | Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors V | |
| JP2014523880A5 (enExample) | ||
| JP2014518219A5 (enExample) | ||
| EP2053045A1 (en) | Novel imidazole derivatives | |
| CA3052898A1 (en) | Composition for controlling harmful microorganisms comprising 1 -(phenoxy-pyridinyl)-2-(1,2,4-triazol-1 -yl)-ethanol derivatives | |
| JP2014501717A5 (enExample) | ||
| CA2727528A1 (en) | Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system | |
| US20100022526A1 (en) | Pyridazine derivatives, processes for their preparation and their use as fungicides | |
| JP2014518220A5 (enExample) | ||
| JP2015505538A5 (enExample) | ||
| KR101464420B1 (ko) | 아졸 유도체 및 그의 제조 방법, 상기 유도체의 중간체 화합물 및 그의 제조 방법, 및 상기 유도체를 함유하는 농원예용 약제 및 공업용 재료 보호제 | |
| CN101835773A (zh) | 新颖的咪唑衍生物 | |
| JP2002514646A (ja) | 広範囲抗菌・抗カビ剤としての水溶性アゾール類 | |
| CN101835772B (zh) | 新的咪唑衍生物 | |
| JP2012503005A5 (enExample) | ||
| US20100273804A1 (en) | Pyridazine derivatives useful as fungicides and for the treatment of cancer | |
| WO2009090039A1 (en) | Pyridazine fungicides | |
| WO2009127615A1 (en) | Novel imidazole derivatives having microbiocidal activity | |
| JPWO2012169523A1 (ja) | 農園芸用薬剤、植物病害防除組成物、植物病害防除方法および植物病害防除用製品 |